As the COVID-19 pandemic shows signs of stabilizing, it is imperative for biopharmaceutical companies to reanalyze and recalibrate promotional strategies to align with healthcare professional (HCP) needs.
This paper provides insights from our 3-wave study on HCPs’ evolving outlooks on care delivery and prescription practices, and how they would like to engage with pharmaceutical reps going forward.
Download the Full Report Below
